Exhibit 10.2

September 30, 2026
Matt David, M.D.
Dear Matt,
On behalf of Actinium Pharmaceuticals, Inc. (the “Company”), I am pleased to provide you with this contract (the “Agreement”) related to your position as Chief Financial Officer of the Company. Speaking for myself, as well as the other members of the Company’s management team, we are all very impressed with your credentials and look forward to your future success in this position.
1. Position. The terms of your position with the Company are as set forth below:
(a) You shall serve as Chief Financial Officer. You shall report to the Chief Executive Officer (the “CEO”) or appropriate Company officer, as designated by the CEO, the Board of Directors of the Company (the “Board”) or its representative, and shall perform your duties for the Company at the Company’s offices in New York City or at another location as directed by the Company in accordance with its policies that may be in place from time to time, except for travel that may be necessary or appropriate in connection with the performance of your duties hereunder. The offices of the Company are currently located in New York City at 100 Park Avenue, 23rd Floor, New York, NY 10017.
(b) You agree to devote your best efforts and substantially all of your business time to advance the interests of the Company and to discharge adequately your duties hereunder; provided, that with the advance written consent of the Board, after the one year anniversary of your employment with the Company, you may serve as a director of, or on the advisory committee of no more than one other pharmaceutical or life science company, public or otherwise. Approval for any such business activity shall not be unreasonably withheld by the Board, so long as the activity is not competitive with the business of the Company and does not interfere with the performance of your duties hereunder.
2. Start Date. Subject to fulfillment of any conditions imposed by this Agreement, you will commence employment with the Company on a date mutually agreed by you and the Company (the “Start Date”), which shall be no later than seven (7) days following the effective date of your separation from your current employer, CorMedix Inc. (“CorMedix”). You agree to deliver written notice of resignation to CorMedix within one (1) business day after your execution of this Agreement, and to promptly confirm to the Company that such notice has been delivered. The Company acknowledges that you are subject to a sixty (60) day notice period with CorMedix and that CorMedix may elect to release you before the end of that period. Accordingly, this Agreement shall remain open through the full sixty (60) day notice period, provided that in no event shall the Start Date occur later than December 3, 2026 (the “Outside Start Date”). You agree to keep the Company reasonably informed of your expected separation date, including any early release by CorMedix. The Company may withdraw this Agreement only if (a) you fail to deliver your notice of resignation as provided above, (ii) you fail to commence employment on or before the Outside Start Date, or (iii) you fail to satisfy any other condition set forth in this Agreement. If you fail to commence employment with the Company as provided in this Section 2, the provisions of Attachment C (Failure to Commence Employment) shall apply.
3. Proof of Right to Work. For purposes of federal immigration law, you will be required to provide to the Company documentary evidence of your identity and eligibility for employment in the United States. Such documentation must be provided to us within two (2) business days of your date of hire, or our employment relationship with you may be terminated.
4. Compensation.
(a) Base Salary. Your annual base salary shall be Four Hundred and Fifty Thousand dollars ($450,000), payable in accordance with the Company’s normal payroll practices. The Board shall review the amount of your base salary and performance bonus (as provided below), and shall determine the appropriate adjustments to each component of your compensation each calendar year.
(b) Sign on Bonus. You will be eligible for a payment of One Hundred Thousand dollars ($100,000) payable upon the condition of providing Proof of Right to Work pursuant to Section 3 and fulfilling the Start Date requirement on the first regularly scheduled payroll date following your Start Date, and an additional payment of Fifty Thousand dollars ($50,000) payable on the Company’s last regularly scheduled payroll date in December 2026, subject to your continued employment with the Company through such payment date (together, the “Sign on Bonus”), and subject to the repayment conditions in this Section 4(b). By accepting the Sign on Bonus, you acknowledge and agree that the Company anticipates, and should receive, the opportunity to derive the benefit of your services in exchange for providing you with the Sign on Bonus. In the event your employment with the Company ceases as a result of your resignation without Good Reason or the termination of your employment by the Company with Cause: (i) within 12 months of your Start Date, you agree to return to Actinium the entire amount of the Sign on Bonus paid to you; or (ii) after 12 months of your Start Date but before 24 months of your Start Date, you agree to return to the Company a pro-rated amount of the Sign on Bonus paid to you based on length of service on an after-tax basis. For clarity purposes, for purposes of subsection (ii) in the foregoing sentence, if for example you or the Company elect to terminate employment as provided herein 18 months (Eighteen months) after your Start Date, you would be required to return $37,500 (Thirty-Seven Thousand Five Hundred dollars), which is calculated by dividing $150,000 (One Hundred Fifty Thousand dollars) by 24 months (Twenty-Four months) and multiplying that amount by the unearned 6 months (Six months). For the avoidance of doubt, the repayment periods set forth in this Section 4(b) shall be measured from your Start Date for both payments, regardless of the date on which each payment is made. Any amounts due will be repayable to the Company on an after-tax basis within 30 days from the end of employment.
(c) Performance Bonus. You shall be entitled to participate in an employee bonus program, which shall be established by the Board pursuant to which the Board may award bonuses to you at a target of Forty Percent (40%) of your annual base salary, based upon the achievement of written individual and corporate objectives as the Board shall determine in consultation and agreement with the CEO. For calendar year 2026, you shall receive your full target bonus of Forty Percent (40%) of your annual base salary, pro-rated for the portion of 2026 during which you are employed and without regard to the achievement of individual or corporate objectives (the “2026 Pro-Rated Bonus”), payable at the same time 2026 bonuses are paid to the Company’s other executive officers, subject to your continued employment through the payment date.
| 2 |
(d) Stock Option Grant. The Board has agreed to grant you an option grant to purchase no less than Two Hundred Fifty Thousand (250,000) common shares of the Company (the “Option Grant”) under the Actinium Pharmaceuticals, Inc. 2026 Employment Inducement Award Plan (the “Inducement Plan”). The Option Grant and the RSU Grants described in Section 4(e) below are being granted as an inducement material to your entering into employment with the Company in accordance with Section 711(a) of the NYSE American Company Guide, and not under the Company’s Amended and Restated 2019 Stock Plan and will be registered on a Form S-8 Registration Statement.
(i) Stock Options. The Option Grant will have an exercise price equal to the closing price of the Company’s common stock on the Start Date (the “Grant Date”).
(ii) Vesting Schedule. Twenty-eight percent (28%) of the Option Grant shall vest twelve (12) months after the Grant Date and two percent (2%) of the Option Grant shall vest each month thereafter, subject to your continuing service to the Company on each applicable vesting date. The term of all options granted under this Agreement will be for 10 years from the Grant Date. The Option Grant will be a non-qualified stock option and will be subject to the terms of the Inducement Plan and the Nonqualified Stock Option Agreement between you and the Company.
(e) Restricted Stock Units Grant. The Board has agreed to grant you an award of up to Three Hundred Twenty-Five Thousand (325,000) Restricted Stock Units (“RSUs”) under the Inducement Plan which shall be granted on your Start Date and may be converted into the number of common shares of the Company equal to the number of RSUs (the “RSU Grants”).
(i) Restricted Stock Units. Such RSU will have a value equal to the fair market value of a common share of the Company at any time.
(ii) Vesting of the RSU Grants. The RSU Grants shall vest as set forth below, subject to your continuing service with the Company on each applicable vesting date. The award will convert to shares of the Company subject to the terms of the Inducement Plan and the applicable Restricted Stock Unit Award Agreement between you and the Company.
(A) Initial RSU Grant. One Hundred Twenty-Five Thousand (125,000) RSUs, which shall vest in three (3) equal annual installments on each of the first, second and third anniversaries of the Grant Date, subject to your continuing service to the Company on each applicable vesting date.
(B) Retention RSU Grant. One Hundred Twenty-Five Thousand (125,000) RSUs, which shall vest in full on the third (3rd) anniversary of the Grant Date, subject to your continuing service to the Company on the applicable vesting date.
| 3 |
(C) Financing RSU Grant. Seventy-Five Thousand (75,000) RSUs (the “Financing RSUs”), which shall vest upon the closing by the Company, on or before February 5, 2027, of a bona fide financing with one or more third-party investors consisting solely of the sale of shares of the Company’s common stock, in a single transaction or a series of related transactions, yielding aggregate gross proceeds to the Company of either (1) at least Twenty Million dollars ($20,000,000) but less than Thirty Million dollars ($30,000,000), in which case Fifty Thousand (50,000) of the Financing RSUs shall vest, or (2) at least Thirty Million dollars ($30,000,000), in which case all Seventy-Five Thousand (75,000) of the Financing RSUs shall vest, subject to your continuing service to the Company on the applicable vesting date. Any Financing RSUs that have not vested on or before February 5, 2027 shall be forfeited.
(f) Claw-back. Any bonus, equity award or other incentive-based compensation paid or granted to you shall be subject to the Company’s claw-back and recoupment policy as in effect from time to time, including any policy adopted to comply with Section 10D of the Securities Exchange Act of 1934, as amended, and the listing standards of the NYSE American, and to any recoupment required by applicable law.
5. Benefits.
(a) Benefit Plans. The Company will provide you with the opportunity to participate in the standard benefit plans currently available to other senior executives, including health, disability and life insurance plans. The Company reserves the right to cancel and/or change the benefits plans it offers to its employees at any time, subject to applicable law.
(b) Vacation; Sick Leave. You will be entitled to twenty (20) days paid vacation per year. Vacation may not be taken before it is accrued. You will be entitled to five (5) days paid sick leave per year. You may carry over a maximum of five (5) days of paid vacation days and five (5) days of paid sick leave time in accordance with the Company’s vacation and sick leave policy.
(c) Reimbursement of Expenses. You shall be reimbursed for all normal items of travel and entertainment and miscellaneous expenses reasonably incurred by you on behalf of the Company provided such expenses are documented and submitted in accordance with the reimbursement policies in effect from time to time.
6. Confidential Information and Invention Assignment Agreement. As a condition of your employment, you agree to execute the Company’s Confidential Information and Invention Assignment Agreement, a copy of which is attached hereto as Attachment B (the “Confidentiality Agreement”).
7. At-Will Employment. Your employment with the Company will be on an “at will” basis, meaning that either you or the Company may terminate your employment at any time for any reason or no reason, without further obligation or liability, except as set forth in this Agreement or any applicable equity plan or equity agreement.
8. Non-Competition. During the term of your employment with the Company and for a period of twenty-four (24) months following the cessation of your employment with the Company for any reason or no reason, you shall not, either directly or indirectly, engage (as principal, partner, employee, consultant, owner, independent contractor, advisor or otherwise, with or without compensation) in any radiopharmaceutical companies or companies pursuing the same biologic targets (the “Competing Business”). Notwithstanding the foregoing, this does not prevent you from being engaged or employed with a business that has a Competing Business as part of its business if such Competing Business is an immaterial part of the business or so long as you are not engaged or involved in any way in the Competing Business at such business or enterprise.
| 4 |
9. Non-Solicitation. You agree that during the term of your employment with the Company, and for a period of twenty-four (24) months following the cessation of employment with the Company for any reason or no reason, you shall not directly or indirectly solicit, induce, recruit or encourage any of the Company’s employees or consultants to terminate their relationship with the Company, or attempt any of the foregoing, either for yourself or any other person or entity. For a period of twenty-four (24) months following cessation of employment with the Company for any reason or no reason, you shall not attempt to negatively influence any of the Company’s clients or customers from purchasing Company products or services or to solicit or influence or attempt to influence any client, customer or other person either directly or indirectly, to direct his or its purchase of products and/or services to any person, firm, corporation, institution or other entity in competition with the business of the Company.
10. Arbitration. Any dispute or claim arising out of or in connection with your employment with the Company (except with regard to enforcement of the Confidentiality Agreement) will be finally settled by arbitration in New York, New York in accordance with the Commercial Arbitration Rules of the American Arbitration Association by one arbitrator appointed in accordance with said rules; provided that the Company shall pay all arbitration-related fees, administrative costs and arbitrator compensation (but not, for the avoidance of doubt, your initial filing fee not to exceed an amount equal to the standard court filing fee, or your attorney or witness fees). Judgment on the award rendered by the arbitrator may be entered in any court having jurisdiction thereof. The parties agree that this Agreement evidences a transaction involving interstate commerce and that the operation, interpretation and enforcement of this arbitration provision, the procedures to be used in conducting an arbitration pursuant to this arbitration provision, and the confirmation of any award issued to either party by reason of such arbitration, is governed exclusively by the Federal Arbitration Act, 9 U.S.C. § 1 et seq. Notwithstanding the foregoing, the parties may apply to any court of competent jurisdiction for preliminary or interim equitable relief, or to compel arbitration in accordance with this paragraph, without breach of this arbitration provision.
11. Miscellaneous. This Agreement, together with the Confidentiality Agreement, the equity documentation and the Indemnification Agreement to be entered into, sets forth the terms of your employment with the Company and supersedes any prior representations or agreements, whether written or oral. This Agreement may not be modified or amended except by a written agreement, signed by the Company and by you. Whenever possible, each provision of this Agreement will be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Agreement is held to be invalid, illegal or unenforceable in any respect under any applicable law or rule in any jurisdiction, such invalidity, illegality or unenforceability will be lessened or reduced to the extent possible or will be severed and will not affect any other provision and this Agreement will be reformed, construed and enforced in such jurisdiction as if such invalid, illegal or unenforceable provision had never been contained herein. This Agreement will be governed by New York law without reference to rules of conflicts of law. All notices, requests, demands and other communications called for hereunder shall be in writing and shall be deemed given (i) on the date of delivery if delivered personally, (ii) one (1) day after being sent by a well-established commercial overnight service, (iii) three (3) days after being mailed by registered or certified mail, return receipt requested, prepaid and addressed to the parties or their successors at the following addresses, or at such other addresses as the parties may later designate in writing, (iv) upon confirmation of facsimile transfer, if sent by facsimile or (v) upon confirmation of delivery when directed to the electronic mail address set forth below, if sent by electronic mail:
| If to the Company: | Human Resources | |
100 Park Avenue, 23rd Floor New York, NY 10017 | ||
| If to you: | Matt David at the address set forth in the Company’s records |
| 5 |
12. Change in Control. If the Company terminates your employment other than for death, Disability (as defined below), or Cause (as defined below), or if you resign for Good Reason (as defined below), in any case during the 24-month period beginning on the date of a Change in Control (as defined in the Company’s Amended and Restated 2019 Stock Plan), you shall be entitled to the following, subject to Section 13 hereof:
(a) A single lump sum payment equal to one and one-half (1.5) times the sum of (i) your annual base salary and (ii) your target annual bonus for the year of termination (in both instances at the rate in effect as of the date of termination without giving effect to any reduction that gave rise to your resignation for Good Reason), plus (iii) any annual bonus for the calendar year preceding the year of termination that has not been paid as of the date of termination and (iv) if the date of termination occurs prior to payment of the 2026 Pro-Rated Bonus, the 2026 Pro-Rated Bonus, payable within thirty (30) business days following the date the Release (as defined in Section 13 hereof) becomes effective and irrevocable in accordance with its terms.
(b) Continued health benefits for the 18-month period beginning on the date of termination, with such period to run concurrently with any period for which you are eligible to elect health coverage under the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended (“COBRA”). During this 18-month continuation period, the Company will subsidize your COBRA premiums in an amount equal to what it would have paid toward health insurance premiums for an active employee with similar coverage. Notwithstanding the foregoing, you shall be required to pay any and all service provider premiums associated with COBRA coverage and, if you begin providing services to another service recipient and become covered by such service recipient’s health benefits plan or program, the continued health benefits and Company subsidy provided hereunder shall cease.
(c) All outstanding equity awards granted to you under the Company’s equity compensation plans shall become immediately vested and exercisable (as applicable) as of the date of such termination, the performance goals with respect to such outstanding performance awards, if any, will be deemed satisfied at “target”, and all outstanding and vested Company stock options (including those that vest pursuant to the operation of this paragraph) will remain exercisable for the full duration of their term.
(d) “Cause” means: (i) your willful failure, disregard or refusal to perform your material duties or obligations under this Agreement (other than as a result of your mental incapacity or illness, as confirmed by medical evidence provided by a physician selected by the Company); (ii) your gross negligence and/or willful misconduct (as such terms are generally understood and applied to the performance of an executive) in the performance of your material duties with respect to the Company, as determined with respect to (i) and (ii) by a court of competent jurisdiction not subject to further appeal or a final arbitration award as provided hereunder; (iii) the conviction by you of a crime constituting a felony, or (iv) you shall have committed any material act of malfeasance, dishonesty or breach of fiduciary duty against the Company, for which you shall have a thirty (30) day cure period following notice thereof from the Company (except for a conviction pursuant to subsection (iii), for which there shall be no cure period).
| 6 |
(e) “Good Reason” means: (i) the Company’s material breach of any of its obligations under this Agreement; (ii) a material reduction of your base salary or target bonus opportunity; (iii) a material negative change to your title, reporting relationship, authority, duties or the scope of your work, (provided, however, that a material reduction in your title, reporting relationship, authority, duties or scope of work during the twelve (12) month period following a Change in Control primarily by virtue of the Company being made part of a larger entity (whether as a subsidiary, business unit or otherwise) will not constitute Good Reason); or (iv) the Company’s regular requirement that you perform services in or relocate to a location that is more than twenty-five (25) miles from New York City. A termination will not be deemed to be for Good Reason unless the Company does not cure within 30 days after receipt of written notice from you specifying the Good Reason and referring to your right to resign for Good Reason. Any resignation for Good Reason will be effective immediately upon your giving notice of your resignation for Good Reason to the Company, conditioned upon your having provided proper notice of Good Reason and time to cure in accordance with this provision.
(f) “Disability” means that (i) you have been unable, for a period of 180 consecutive business days, to perform your duties under this Agreement, as a result of physical or mental illness or injury, and (ii) a physician selected or approved by the Company has determined that it is either not possible to determine when such inability to perform will cease or that it appears probable that such inability will be permanent during the remainder of your life.
(g) Mitigation. In the event that you are entitled to severance pursuant to this Agreement, you have no duty to mitigate and your severance will not be reduced for any reason.
12A. Severance Not in Connection with a Change in Control. If the Company terminates your employment other than for death, Disability, or Cause, or if you resign for Good Reason, in any case in circumstances other than those described in Section 12, you shall be entitled to the following, subject to Section 13 hereof:
(a) Continued payment of your annual base salary (at the rate in effect as of the date of termination without giving effect to any reduction of your base salary that gave rise to your resignation for Good Reason) for a period of nine (9) months following the date of termination, payable in substantially equal installments in accordance with the Company’s regular payroll practices, commencing on the first regularly scheduled payroll date following the sixtieth (60th) day after the date of termination; provided that the first installment shall include all amounts that would otherwise have been paid from the date of termination through such first payment date.
(b) Continued health benefits for the 9-month period beginning on the date of termination, on the same terms and subject to the same conditions set forth in Section 12(b).
(c) (i) Any annual bonus for the calendar year preceding the year of termination that has not been paid as of the date of termination, based on actual achievement as determined by the Board; (ii) if the date of termination occurs prior to payment of the 2026 Pro-Rated Bonus, the 2026 Pro-Rated Bonus; and (iii) a pro-rated annual bonus for the year of termination, based on actual achievement of the applicable objectives as determined by the Board, multiplied by a fraction, the numerator of which is the number of days you were employed during such year and the denominator of which is 365. The amounts under clauses (i) and (iii) shall be paid at the same time annual bonuses are paid to the Company’s other executive officers, but in no event later than March 15 of the calendar year following the year to which such bonus relates, and the amount under clause (ii) shall be paid in accordance with Section 4(c).
| 7 |
(d) All outstanding equity awards granted to you under the Company’s equity compensation plans that are scheduled to vest within twelve (12) months following the date of termination shall become immediately vested and exercisable (as applicable) as of the date of such termination; provided that any award subject to performance-based vesting conditions, including the Financing RSUs, shall vest only to the extent such conditions have been satisfied as of the date of termination.
13. Release. Notwithstanding anything contained herein to the contrary, the Company shall not be obligated to provide any severance payment or benefit under Section 12(a), (b) or (c) or Section 12A hereof unless: (a) you or your legal representative first executes within fifty (50) calendar days after the date of presentment a release of claims agreement in the form as to be provided by the Company (the “Release”) and substantially similar to the form of Release attached hereto as Attachment A, (b) you do not revoke the Release, and (c) the Release becomes effective and irrevocable in accordance with its terms. The Company shall provide the Release to you for your review within ten (10) days of the date of termination.
14. Section 280G. In the event it shall be determined that any payment or distribution by the Company to or for your benefit (whether paid or payable or distributed or distributable pursuant to the terms of this Agreement or otherwise) (the “Total Payments”), is or will be subject to the excise tax (the “Excise Tax”) imposed by Section 4999 of the Internal Revenue Code of 1986, as amended (the “Code”), then the Total Payments shall be reduced to the maximum amount that could be paid to you without giving rise to the Excise Tax (the “Safe Harbor Cap”), if the net after-tax benefit to you after reducing your Total Payments to the Safe Harbor Cap is greater than the net after-tax (including the Excise Tax) benefit to you without such reduction. The reduction of the amounts payable hereunder, if applicable, shall be made by reducing such payment that trigger the Excise Tax in the following order: (i) reduction of cash payments, (ii) cancellation of accelerated vesting of performance-based equity awards (based on the reverse order of the date of grant), (iii) cancellation of accelerated vesting of other equity awards (based on the reverse order of the date of grant), and (iv) reduction of any other payments due to you (with benefits or payments in any group having different payment terms being reduced on a pro-rata basis). All mathematical determinations, and all determinations as to whether any of the Total Payments are “parachute payments” (within the meaning of Section 280G of the Code), that are required to be made under this paragraph, including determinations as to whether the Total Payments to you shall be reduced to the Safe Harbor Cap and the assumptions to be utilized in arriving at such determinations, shall be made at the Company’s expense by the Company’s then current independent auditors, or such other nationally recognized accounting firm selected by the Compensation Committee of the Board prior to the relevant change in control transaction. The independent auditors or accounting firm, as applicable, shall, at the Company’s expense, do a valuation of your obligations under Sections 8 and 9 and any other non-competition or non-solicitation agreements or provisions executed by you in favor of the Company, to be used, if necessary, to minimize or eliminate the need to reduce any Total Payments.
| 8 |
15. Section 409A.
(a) In General. It is the Company’s intent that this Agreement be exempt from the application of, or otherwise comply with, the requirements of Section 409A of the Code (“Section 409A”). Specifically, any taxable benefits or payments provided under this Agreement are intended to be separate payments that qualify for the “short-term deferral” exception to Section 409A to the maximum extent possible, and to the extent they do not so qualify, are intended to qualify for the involuntary separation pay exceptions to Section 409A, to the maximum extent possible. If neither of these exceptions applies, and if you are a “specified employee” within the meaning of Section 409A, then notwithstanding any provision in this Agreement to the contrary and to the extent required to comply with Section 409A, all amounts that would otherwise be paid or provided to you during the first six (6) months following your date of termination shall instead be accumulated through and paid or provided (without interest) on the first business day following the six-month anniversary of the date of termination. If the period during which the Release must become effective and irrevocable in accordance with its terms spans two calendar years, then, to the extent required to comply with Section 409A, any payment to be made under this Agreement will commence on the first payroll date that occurs in the second calendar year and after the Release has become effective and irrevocable in accordance with its terms. Further, to the extent required to comply with Section 409A: (i) the amount of any expense reimbursement to which you may be entitled hereunder during a calendar year will not affect the amount of reimbursements to be provided in any other calendar year; (ii) your right to receive reimbursement of an eligible expense hereunder is not subject to liquidation or exchange for another benefit; and (iii) provided that the requisite documentation is submitted, the Company will reimburse your eligible expenses on or before the last day of the calendar year following the calendar year in which the expense was incurred. If under this Agreement an amount is paid in two (2) or more installments, for purposes of Section 409A, each installment will be treated as a separate and distinct payment. All severance benefits will be completed by, and no further severance benefits will be payable after, December 31 of the second taxable year following the year in which your termination of employment occurs.
(b) Separation from Service. A termination of service shall not be deemed to have occurred for purposes of any provision of this Agreement providing for the payment of any amounts or benefits subject to Section 409A upon or following a termination of service unless such termination is also a “separation from service” within the meaning of Section 409A and you are no longer providing services (at a level that would preclude the occurrence of a “separation from service” within the meaning of Section 409A) to the Company or its affiliates as an employee or consultant, and for purposes of any such provision of this Plan, references to a “termination,” “termination of employment” or like terms shall mean “separation from service” within the meaning of Section 409A.
16. Withholding of Taxes. The Company may withhold from any amounts payable under this Agreement all federal, state, city or other taxes as the Company may be required to withhold pursuant to any law or government regulation or ruling.
[Signature Page Follows]
| 9 |
To indicate your acceptance of the Company’s offer, please sign and date this letter in the space provided below and return it to me.
Very truly yours,
| ACTINIUM PHARMACEUTICALS, INC. | ||
| By: | /s/ Sandesh Seth | |
| Sandesh Seth | ||
| Title: | Chairman and Chief Executive Officer | |
| Accepted and Agreed: | ||
| By: | /s/ Matt David, M.D. | |
| Name: | Matt David, M.D. | |
| 10 |
ATTACHMENT
A
RELEASE OF CLAIMS
FOR AND IN CONSIDERATION OF the payments and benefits (the “Separation Benefits”) to be provided to me in connection with the separation of my relationship with the Company, in accordance with the Agreement between Actinium Pharmaceuticals, Inc. (the “Company”) and me dated as of September 30, 2026 (the “Agreement”), which Separation Benefits are conditioned on my signing this Release of Claims (“Release”) and which I will forfeit unless I execute and do not revoke this Release of Claims, I, on my own behalf and on behalf of my heirs and estate, voluntarily, knowingly and willingly release and forever discharge the Company, its subsidiaries, affiliates, parents, and stockholders, together with each of those entities’ respective officers, directors, stockholders, employees, agents, fiduciaries and administrators (collectively, the “Releasees”) from any and all claims and rights of any nature whatsoever which I now have against them up to the date I execute this Release, whether known or unknown, suspected or unsuspected. This Release includes, but is not limited to, any rights or claims relating in any way to my employment or consulting relationship with the Company or any of the other Releasees or the termination thereof, any contract claims (express or implied, written or oral), including, but not limited to, the Agreement, or any rights or claims under any statute, including, without limitation, the Americans with Disabilities Act, the Age Discrimination in Employment Act, the Older Workers’ Benefit Protection Act, the Rehabilitation Act of 1973 (including Section 504 thereof), Title VII of the 1964 Civil Rights Act, the Civil Rights Act of 1866 (42 U.S.C. § 1981), the Civil Rights Act of 1991, the Equal Pay Act, the National Labor Relations Act, the Worker Adjustment and Retraining Notification Act, the Family Medical Leave Act, the Lilly Ledbetter Fair Pay Act, the Genetic Information Non-Discrimination Act, the New York State Human Rights Law, the New York City Human Rights Law, and the Employee Retirement Income Security Act of 1974, all as amended, and any other federal, state or local law. This Release specifically includes, but is not limited to, any claims based upon the right to the payment of wages, incentive and performance compensation, bonuses, equity grants, vacation, pension benefits, 401(k) Plan benefits, stock benefits or any other employee benefits, or any other rights arising under federal, state or local laws prohibiting discrimination and/or harassment on the basis of race, color, age, religion, sexual orientation, religious creed, sex, national origin, ancestry, alienage, citizenship, nationality, mental or physical disability, denial of family and medical care leave, medical condition (including cancer and genetic characteristics), marital status, military status, gender identity, harassment or any other basis prohibited by law.
As a condition of the Company entering into this Release, I further represent that I have not filed against the Company or any of the other Releasees, any complaints, claims or lawsuits with any arbitral tribunal, administrative agency, or court prior to the date hereof, and that I have not transferred to any other person any such complaints, claims or lawsuits. I understand that by signing this Release, I waive my right to any monetary recovery in connection with a local, state or federal governmental agency proceeding and I waive my right to file a claim seeking monetary damages in any arbitral tribunal, administrative agency, or court. This Release does not: (i) prohibit or restrict me from communicating, providing relevant information to or otherwise cooperating with the U.S. Equal Employment Opportunity Commission or any other governmental authority with responsibility for the administration of fair employment practices laws or other governmental or law enforcement agency or entity (including, without limitation, the Securities and Exchange Commission) regarding a possible violation of such laws or responding to any inquiry from such authority, including an inquiry about the existence of this Release or its underlying facts, or (ii) require me to notify the Company of such communications or inquiry. Furthermore, notwithstanding the foregoing, this Release does not include and will not preclude: (a) rights or claims to vested benefits under any applicable retirement and/or pension plans; (b) rights under the Consolidated Omnibus Budget Reconciliation Act of 1985 (“COBRA”); (c) claims for unemployment compensation; (d) rights to defense and indemnification, if any, from the Company for actions or inactions taken by me in the course and scope of my employment with the Company and its parents, subsidiaries and/or affiliates; (e) any rights I may have to obtain contribution as permitted by law in the event of entry of judgment against the Company as a result of any act or failure to act for which I and the Company are held jointly liable; (f) the right to any equity awards that vested prior to or because of the termination of my employment, (g) the right to any whistleblower award pursuant to Section 21F of the Securities Exchange Act of 1934 or any other similar provision, and/or (h) any actions to enforce the Agreement.
| 11 |
Nothing herein shall be construed to limit my right to (1) respond accurately and fully to any question, inquiry or request for information when required by legal process; or (2) disclose information to regulatory bodies. I understand that I am not required to contact the Company before engaging in such communications.
I acknowledge that, in signing this Release, I have not relied on any promises or representations, express or implied, other than those that are set forth expressly herein or in the Agreement and that are intended to survive separation from employment, in accordance with the terms of the Agreement.
I further acknowledge that:
1. I first received this Release on the date of the Agreement to which it is attached as Attachment A;
2. I understand that, in order for this Release to be effective, I may not sign it prior to the date of my separation of employment with the Company but that if I wish to receive the Separation Benefits, I must sign and return this Release within 21 days of its presentation to me after my termination of employment;
3. I have carefully read and understand this Release;
4. The Company advised me to consult with an attorney and/or any other advisors of my choice before signing this Release;
5. I understand that this Release is LEGALLY BINDING and by signing it I give up certain rights;
6. I have voluntarily chosen to enter into this Release and have not been forced or pressured in any way to sign it;
7. I acknowledge and agree that the Separation Benefits are contingent on execution of this Release, which releases all of my claims against the Company and the Releasees, and I KNOWINGLY AND VOLUNTARILY AGREE TO RELEASE the Company and the Releasees from any and all claims I may have, known or unknown, in exchange for the benefits I have obtained by signing, and that these benefits are in addition to any benefit I would have otherwise received if I did not sign this Release;
8. I have seven (7) days after I sign this Release to revoke it by notifying the Company in writing. The Release will not become effective or enforceable until the seven (7) day revocation period has expired;
9. This Release includes a WAIVER OF ALL RIGHTS AND CLAIMS I may have under the Age Discrimination in Employment Act of 1967 (29 U.S.C. §621 et seq.); and
10. This Release does not waive any rights or claims that may arise after this Release becomes effective, which is seven (7) days after I sign it, provided that I do not exercise my right to revoke this Release.
Intending to be legally bound, I have signed this Release as of the date written below.
| Signature: | Date Signed: |
| 12 |
ATTACHMENT B
Actinium Pharmaceuticals, Inc.
CONFIDENTIAL INFORMATION AND
INVENTION ASSIGNMENT AGREEMENT
As a condition of my becoming employed by Actinium Pharmaceuticals, Inc., a Delaware corporation, or any of its current or future subsidiaries, affiliates, successors or assigns (collectively, the “Company”), and in consideration of my employment with the Company and my receipt of the compensation now and hereafter paid to me by the Company, I agree to the following:
1. Employment Relationship. I understand and acknowledge that this Agreement does not alter, amend or expand upon any rights I may have to continue in the employ of, or the duration of my employment relationship with, the Company under any existing agreements between the Company and me or under applicable law. Any employment relationship between the Company and me, whether commenced prior to or upon the date of this Agreement, shall be referred to herein as the “Relationship.”
2. Duties. I will perform for the Company such duties as may be designated by the Company from time to time. During the Relationship, I will devote my best efforts to the interests of the Company and will not engage in other employment or in any activities detrimental to the best interests of the Company without the prior written consent of the Company.
3. At-Will Relationship. I understand and acknowledge that my Relationship with the Company is and shall continue to be at-will, as defined under applicable law, meaning that either I or the Company may terminate the Relationship at any time for any reason or no reason, without further obligation or liability.
4. Confidential Information.
(a) Company Information. I agree at all times during the term of my Relationship with the Company and thereafter, to hold in strictest confidence, and not to use, except for the benefit of the Company to the extent necessary to perform my obligations to the Company under the Relationship, or to disclose to any person, firm, corporation or other entity without written authorization of the Board of Directors of the Company, any Confidential Information of the Company which I obtain or create. I further agree not to make copies of such Confidential Information except as authorized by the Company. I understand that “Confidential Information” means any Company proprietary information, technical data, trade secrets or know-how, including, but not limited to, research, product plans, products, services, suppliers, customer lists and customers (including, but not limited to, customers of the Company on whom I called or with whom I became acquainted during the Relationship), prices and costs, markets, software, developments, inventions, laboratory notebooks, processes, formulas, technology, designs, drawings, engineering, hardware configuration information, marketing, licenses, finances, budgets or other business information disclosed to me by the Company either directly or indirectly in writing, orally or by drawings or observation of parts or equipment or created by me during the period of the Relationship, whether or not during working hours. I understand that “Confidential Information” includes, but is not limited to, information pertaining to any aspects of the Company’s business which is either information not known by actual or potential competitors of the Company or other third parties not under confidentiality obligations to the Company, or is otherwise proprietary information of the Company or its customers or suppliers, whether of a technical nature or otherwise. I further understand that Confidential Information does not include any information which has become publicly known and made generally available through no wrongful act of mine, was known to me at the time it was disclosed, is lawfully and in good faith made available to me by a third party who did not derive it, directly or indirectly from the Company, or is information that is independently discovered or developed by me without violating my obligations under this agreement and which can be demonstrated by competent evidence.
| 13 |
(b) Prior Obligations. I represent that my performance of all terms of this Agreement as an employee of the Company has not breached and will not breach any agreement to keep in confidence information acquired by me prior or subsequent to the commencement of my Relationship with the Company, and I will not disclose to the Company or use any inventions, confidential or non-public proprietary information or material belonging to any previous client, employer or any other party. I will not induce the Company to use any inventions, confidential or non-public proprietary information or material belonging to any previous client, employer or any other party. I acknowledge and agree that I have in good faith listed on Exhibit B all agreements (e.g., non-competition agreements, non-solicitation of customers agreements, non-solicitation of employees agreements, confidentiality agreements, inventions agreements, etc.) with a current or former employer, or any other person or entity, that may reasonably restrict my ability to recruit or engage customers or service providers on behalf of the Company, or otherwise relate to or restrict my ability to perform my duties as an employee of the Company or any obligation I may have to the Company.
(c) Third Party Information. I recognize that the Company has received and in the future will receive confidential or proprietary information from third parties subject to a duty on the Company’s part to maintain the confidentiality of such information and to use it only for certain limited purposes. I agree to hold all such confidential or proprietary information in the strictest confidence and not to disclose it to any person, firm or corporation or to use it except as necessary in carrying out my work for the Company consistent with the Company’s agreement with such third party.
5. Inventions.
(a) Inventions Retained and Licensed. I have in good faith and to best of my knowledge attached hereto, as Exhibit A, a list describing with particularity all inventions, original works of authorship, developments, improvements, and trade secrets which were made by me prior to the commencement of the Relationship (collectively referred to as “Prior Inventions”), which belong solely to me or belong to me jointly with another, which as of the execution of this agreement may reasonably relate in any way to any of the Company’s proposed businesses, products or research and development, and which are not assigned to the Company hereunder; or, if no such list is attached, I represent that there are no such Prior Inventions. If, in the course of my Relationship with the Company, I incorporate into a Company product, process or machine a Prior Invention owned by me or in which I have an interest, the Company is hereby granted and shall have a non-exclusive, royalty-free, irrevocable, perpetual, worldwide license (with the right to sublicense) to make, have made, copy, modify, make derivative works of, use, sell and otherwise distribute such Prior Invention as part of or in connection with such product, process or machine.
| 14 |
(b) Assignment of Inventions. I agree that I will promptly make full written disclosure to Company, will hold in trust for the sole right and benefit of the Company, and hereby assign to Company, or its designee, all my right, title and interest throughout the world in and to any and all inventions related to the Company’s technology or development programs as currently operated or contemplated, original works of authorship, developments, concepts, know-how, improvements or trade secrets, whether or not patentable or registrable under copyright or similar laws, which I may solely or jointly conceive or develop or reduce to practice, or cause to be conceived or developed or reduced to practice, during the period of time in which I am employed by the Company (collectively referred to as “Inventions”), except as provided in Exhibit A. I further acknowledge that all inventions, original works of authorship, developments, concepts, know-how, improvements or trade secrets which are made by me (solely or jointly with others) within the scope of and directly related to Company’s technology or development programs as currently operated or contemplated and during the period of my Relationship with the Company are “works made for hire” (to the greatest extent permitted by applicable law) and are compensated by my salary (if I am an employee), unless regulated otherwise by the mandatory law of the State of New York.
(c) Maintenance of Records. I agree to keep and maintain adequate and current written records of all Inventions made by me (solely or jointly with others) during the term of my Relationship with the Company. The records may be in the form of notes, sketches, drawings, flow charts, electronic data or recordings, laboratory notebooks, and any other format. The records will be available to and remain the sole property of the Company at all times. I agree not to remove such records from the Company’s place of business except as expressly permitted by Company policy which may, from time to time, be revised at the sole election of the Company for the purpose of furthering the Company’s business. I agree to return all such records (including any copies thereof) to Company at the time of termination of my Relationship with the Company as provided for in Section 6.
(d) Patent and Copyright Rights. I agree to assist Company, or its designee, at its expense, in every proper way to secure Company, or its designee’s, rights in the Inventions and any copyrights, patents, trademarks, mask work rights, moral rights, or other intellectual property rights relating thereto in any and all countries, including the disclosure to Company, or its designee of all pertinent information and data with respect thereto, the execution of all applications, specifications, oaths, assignments, recordations, and all other instruments which Company or its designee shall deem necessary in order to apply for, obtain, maintain and transfer such rights and in order to assign and convey to Company or its designee and any successors, assigns and nominees the sole and exclusive rights, title and interest in and to such Inventions, and any copyrights, patents, mask work rights or other intellectual property rights relating thereto. I further agree that my obligation to execute or cause to be executed, when it is in my power to do so, any such instrument or papers shall continue after the termination of this Agreement until the expiration of the last such intellectual property right to expire in any country of the world. If the Company or its designee is unable because of my mental or physical incapacity or unavailability or for any other reason to secure my signature to apply for or to pursue any application for any United States or foreign patents, copyright, mask works, or other registrations covering Inventions or original works of authorship assigned to Company or its designee as above, then I hereby irrevocably designate and appoint Company and its duly authorized officers and agents as my agent and attorney in fact, to act for and in my behalf and stead to execute and file any such applications and to do all other lawfully permitted acts to further the application for, prosecution, issuance, maintenance or transfer of letters patent, copyright or other registrations thereon with the same legal force and effect as if originally executed by me. I hereby waive and irrevocably quitclaim to Company or its designee any and all claims, which I now or hereafter have for infringement of any and all proprietary rights assigned to Company or such designee.
| 15 |
6. Company Property; Returning Company Documents. I acknowledge and agree that I have no expectation of privacy with respect to the Company’s telecommunications, networking or information processing systems (including, without limitation, stored company files, e-mail messages and voice messages) and that my activity and any files or messages on or using any of those systems may be monitored at any time without notice. I further agree that any property situated on the Company’s premises and owned by the Company, including disks and other storage media, filing cabinets or other work areas, is subject to inspection by Company personnel at any time with or without notice. I agree that, at the time of termination of my Relationship with the Company, I will deliver to the Company (and will not keep in my possession, recreate or deliver to anyone else) any and all devices, records, data, notes, reports, proposals, lists, correspondence, specifications, drawings, blueprints, sketches, laboratory notebooks, materials, flow charts, equipment, other documents or property, or reproductions of any of the aforementioned items, developed by me pursuant to the Relationship or otherwise belonging to the Company, its successors or assigns. In the event of the termination of the Relationship, I agree to sign and deliver the “Termination Certification” attached hereto as Exhibit C, however, my failure to sign and deliver the Termination Certificate shall in no way diminish my continuing obligations under this Agreement.
7. Notification to Other Parties.
(a) Employees. In the event that I leave the employ of the Company, I hereby consent to notification by the Company to my new employer about my rights and obligations under this Agreement.
(b) Consultants. I hereby grant consent to notification by the Company to any other parties besides the Company with whom I maintain a consulting or employment relationship, including parties with whom such relationship commences after the effective date of this Agreement, about my rights and obligations under this Agreement.
8. Representations and Covenants.
(a) Facilitation of Agreement. I agree to execute promptly any proper oath or verify any proper document required to carry out the terms of this Agreement upon the Company’s written request to do so.
(b) Conflicts. I knowingly represent that my performance of all the terms of this Agreement does not and will not breach any agreement I have entered into, or will enter into with any third party, including without limitation any agreement to keep in confidence proprietary information acquired by me in confidence or in trust prior to commencement of my Relationship with the Company. I agree not to enter into any written or oral agreement that conflicts with the provisions of this Agreement.
| 16 |
(c) Voluntary Execution. I certify and acknowledge that I have carefully read all of the provisions of this Agreement and that I understand and will fully and faithfully comply with such provisions.
9. General Provisions.
(a) Governing Law. The validity, interpretation, construction and performance of this Agreement shall be governed by the laws of the State of New York, without giving effect to the principles of conflict of laws.
(b) Entire Agreement. This Agreement sets forth the entire agreement and understanding between the Company and me relating to the subject matter herein and merges all prior discussions between us. No modification or amendment to this Agreement, nor any waiver of any rights under this Agreement, will be effective unless in writing signed by both parties. Any subsequent change or changes in my duties, obligations, rights or compensation will not affect the validity or scope of this Agreement.
(c) Severability. If one or more of the provisions in this Agreement are deemed void by law, then the remaining provisions will continue in full force and effect.
(d) Successors and Assigns. This Agreement will be binding upon my heirs, executors, administrators and other legal representatives, and my successors and assigns, including, any successor entity, and will be for the benefit of the Company, its successors, and its assigns.
(e) Survival. The provisions of this Agreement shall survive the termination of the Relationship and the assignment of this Agreement by the Company to any successor in interest or other assignee.
(f) Remedies. I acknowledge and agree that violation of this Agreement by me may cause the Company irreparable harm, and therefore agree that the Company will be entitled to seek relief in court, including but not limited to temporary restraining orders, preliminary injunctions and permanent injunctions without the necessity of posting a bond or other security and in addition to and without prejudice to any other right and remedies that the Company may have for a breach of this Agreement.
(g) ADVICE OF COUNSEL. I ACKNOWLEDGE THAT, IN EXECUTING THIS AGREEMENT, I HAVE HAD THE OPPORTUNITY TO SEEK THE ADVICE OF INDEPENDENT LEGAL COUNSEL, AND I HAVE READ AND UNDERSTOOD ALL OF THE TERMS AND PROVISIONS OF THIS AGREEMENT. THIS AGREEMENT SHALL NOT BE CONSTRUED AGAINST ANY PARTY BY REASON OF THE DRAFTING OR PREPARATION HEREOF.
[Signature Page Follows]
| 17 |
The parties have executed this Confidentiality and Inventions Assignment Agreement on the respective dates set forth below:
| COMPANY: | EMPLOYEE: |
| ACTINIUM PHARMACEUTICALS, INC. | MATT DAVID, M.D. | |||
| By: | /s/ Sandesh Seth | Signature: | /s/ Matt David, M.D. | |
| Name: | Sandesh Seth | Date: | 9/30/2026 | |
| Title: | Chairman and Chief Executive Officer | |||
| Date: | September 30, 2026 | |||
| 18 |
EXHIBIT A
LIST OF PRIOR INVENTIONS
AND ORIGINAL WORKS OF AUTHORSHIP
EXCLUDED UNDER SECTION 3
| 🗹 | No inventions or improvements | |
| Additional Sheets Attached |
| Signature of Employee: | /s/ Matt David, M.D. | |
| Print Name of Employee: | Matt David, M.D. | |
| Date: | 9/30/2026 |
| 19 |
EXHIBIT B
LIST OF PRIOR AGREEMENTS
| Name of Agreement | Parties to Agreement | Restrictions(s) |
Executive Employment Agreement Dr. Matt David and CorMedix, Inc. Non-solicitation of employees, consultants and independent contractors during the 12-month period following termination of employment.
| Employee’s Signature: | /s/ Matt David, M.D. | |
| Date: | 9/30/2026 |
| 20 |
EXHIBIT C
TERMINATION CERTIFICATION
This is to certify that I do not have in my possession, nor have I failed to return, any devices, records, data, notes, reports, proposals, lists, correspondence, specifications, drawings, blueprints, sketches, laboratory notebooks, flow charts, materials, equipment, other documents or property, or copies or reproductions of any aforementioned items belonging to Actinium Pharmaceuticals, Inc., its subsidiaries, affiliates, successors or assigns (together the “Company”).
I further certify that I have complied with all the terms of the Company’s Confidential Information and Invention Assignment Agreement signed by me, including the reporting of any inventions and original works of authorship (as defined therein), conceived or made by me (solely or jointly with others) covered by that agreement.
I further agree that, in compliance with the Confidential Information and Invention Assignment Agreement, I will preserve as confidential all trade secrets, confidential knowledge, data or other proprietary information relating to products, processes, know-how, designs, formulas, developmental or experimental work, computer programs, data bases, other original works of authorship, customer lists, business plans, financial information or other subject matter pertaining to any business of the Company or any of its employees, clients, consultants or licensees.
I further agree that for twenty four (24) months from the date of this Certificate, I shall not either directly or indirectly solicit, induce, recruit or encourage any of the Company’s employees or consultants to terminate their relationship with the Company, or attempt to solicit, induce, recruit, encourage or take away, hire, or otherwise engage the services of employees or consultants of the Company, either for myself or for any other person or entity. Further, I shall not at any time use any Confidential Information of the Company to negatively influence any of the Company’s clients or customers from purchasing Company products or services or to solicit or influence or attempt to influence any client, customer or other person either directly or indirectly, to direct his or its purchase of products and/or services to any person, firm, corporation, institution or other entity in competition with the business of the Company.
| Date: | |||
| (Employee’s Signature) | |||
| (Type/Print Employee’s Name) |
| 21 |
ATTACHMENT C
Actinium Pharmaceuticals, Inc.
FAILURE TO COMMENCE EMPLOYMENT
You acknowledge that, in reliance on your commitment to commence employment as provided in Section 2 of the Agreement, the Company will end its search for a Chief Financial Officer, forgo other candidates, and plan its financing and other corporate activities around your Start Date, and that the damages the Company would suffer if you fail to commence employment would be difficult to determine with certainty. Accordingly, if, following your execution of the Agreement, you notify the Company that you will not commence employment, or you otherwise fail to commence employment on or before the Outside Start Date (as defined in the Agreement), in either case for any reason other than (i) your death or a physical or mental incapacity that prevents you from commencing employment, (ii) the Company’s withdrawal of the Agreement, or (iii) the Company’s material breach of the Agreement, you shall pay the Company Fifty Thousand Dollars ($50,000) (the “Non-Commencement Fee”) within thirty (30) days after the earlier of such notice or the Outside Start Date. The parties agree that the Non-Commencement Fee represents a reasonable estimate of the Company’s damages, including the costs of reopening its search and engaging interim financial leadership, and is not a penalty, and that payment of the Non-Commencement Fee shall be the Company’s sole and exclusive remedy for your failure to commence employment.
This Attachment C is incorporated into and forms part of the Agreement.
| 22 |